Suchergebnisse - "Bylicki, Olivier"

PubPharm (5)

1

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2023

von Heymach, J. | Harpole, D. | Mitsudomi, T. | +125

CommentIn: N Engl J Med. 2024 Jan 18;390(3):287. - PMID 38231634

2

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

enthalten in: Medicine | 2020

von Bylicki, O. | Guisier, F. | Monnet, I. | +8

3

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2019

von Bylicki, O. | Barazzutti, H. | Paleiron, N. | +3

4

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2) : a multicentre, open-label, randomised, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2019

von Scherpereel, A. | Mazieres, J. | Greillier, L. | +22

CommentIn: Lancet Oncol. 2019 Feb;20(2):172-174. - PMID 30660608

5

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

enthalten in: Targeted oncology | 2017

von Bylicki, O. | Paleiron, N. | Margery, J. | +6

1
[1]